A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis
- PMID: 3309199
- DOI: 10.1200/JCO.1987.5.10.1655
A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis
Abstract
Forty-four patients with documented meningeal carcinomatosis (small-cell lung carcinoma [SCLC], 29%; breast carcinoma, 25%) were treated in a prospective randomized trial with intrathecal methotrexate (MTX) 15 mg or MTX plus cytosine arabinoside (Ara-C) 50 mg/m2. Most patients received intrathecal hydrocortisone (HC) each treatment to minimize arachnoiditis. Overall response was 55%. Seven patients achieved complete response. Response to MTX was superior to combined MTX/Ara-C, but not significantly so (61% v 45%; P greater than .10). Response was more frequent if drugs were administered via Ommaya reservoir than by lumbar puncture (65% v 48%; P greater than .10). Concurrent radiotherapy to the CNS was associated with significantly better response (73% v 35%; P less than .05). Small-cell lung carcinoma patients showed the best response (69%). Overall median survival for the whole group was 8 weeks, but responders fared better than nonresponders (median survival, 18 v 7 weeks; P less than .05). Nausea and vomiting were the most common toxicities encountered (45%), but rarely proved limiting. An unusual, previously undocumented reaction to intrathecal HC was noted. MTX is moderately effective in nonleukemic meningeal carcinomatosis, but the addition of Ara-C does not appear to improve results. Pretreatment factors did not predict outcome in this trial.
Similar articles
-
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.Cancer. 1996 Apr 1;77(7):1315-23. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4. Cancer. 1996. PMID: 8608509 Clinical Trial.
-
Diagnosis and treatment of patients with meningeal carcinomatosis.J Neurooncol. 1992 May;13(1):81-9. doi: 10.1007/BF00172949. J Neurooncol. 1992. PMID: 1613540
-
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone.Jpn J Clin Oncol. 2003 Dec;33(12):608-12. doi: 10.1093/jjco/hyg118. Jpn J Clin Oncol. 2003. PMID: 14769837
-
Intrathecal chemotherapy with antineoplastic agents in children.Paediatr Drugs. 2001;3(4):237-46. doi: 10.2165/00128072-200103040-00001. Paediatr Drugs. 2001. PMID: 11354696 Review.
-
Management of leptomeningeal malignancy.Expert Opin Pharmacother. 2005 Jun;6(7):1115-25. doi: 10.1517/14656566.6.7.1115. Expert Opin Pharmacother. 2005. PMID: 15957966 Review.
Cited by
-
A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.J Neurooncol. 2013 May;113(1):83-92. doi: 10.1007/s11060-013-1092-8. Epub 2013 Mar 1. J Neurooncol. 2013. PMID: 23456656
-
Current options for the treatment of neoplastic meningitis.J Neurooncol. 2002 Oct;60(1):79-88. doi: 10.1023/a:1020200317464. J Neurooncol. 2002. PMID: 12416549 Review.
-
Advances in the diagnosis, evaluation, and management of leptomeningeal disease.Neurooncol Adv. 2021 Nov 27;3(Suppl 5):v86-v95. doi: 10.1093/noajnl/vdab108. eCollection 2021 Nov. Neurooncol Adv. 2021. PMID: 34859236 Free PMC article.
-
Leptomeningeal metastases: a RANO proposal for response criteria.Neuro Oncol. 2017 Apr 1;19(4):484-492. doi: 10.1093/neuonc/now183. Neuro Oncol. 2017. PMID: 28039364 Free PMC article. Review.
-
Leptomeningeal metastatic disease: new frontiers and future directions.Nat Rev Clin Oncol. 2025 Feb;22(2):134-154. doi: 10.1038/s41571-024-00970-3. Epub 2024 Dec 9. Nat Rev Clin Oncol. 2025. PMID: 39653782 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources